See Inside!

List Price

$190.00

Textbook Details

  • EDITION:
    3rd Edition
  • ISBN:
    0123741947
  • ISBN-13:
    9780123741943
  • PUB. DATE:
    July 2008
  • PUBLISHER:
    Elsevier Science
Advertisement

The Practice of Medicinal Chemistry / Edition 3 by Camille Georges Wermuth

$190.00 List Price
  • Overview
  • EditorialReviews
  • Features
  • marketplace

Customer Reviews

  • Customer Rating:
  • Ratings: 1

Be the first to write a review!

Overview -

The Practice of Medicinal Chemistry

Product Details

  • Pub. Date: July 2008
  • Publisher: Elsevier Science
  • Sales Rank: 1,125,667

Synopsis

The second edition of The Practice of Medicinal Chemistry, edited by Professor Camille G Wermuth, provides a unique and comprehensive discussion of the practical problems facing today's medicinal chemists, from the conception of new molecules through to the production of new drugs and their legal/economic implications. The new edition of The Practice of Medicinal Chemistry has been updated, expanded and refocused to reflect developments over the nine years since the first edition was published. Experts in the field give personal accounts of both traditional methodologies and the newest discovery and development technologies providing us with an insight into medicinal chemistry, usually only gained from years of practical experience. This book is essential for organic chemists beginning a career in drug research and for medicinal chemists.

"Having favorably reviewed the first edition, I still highly recommend this third edition to all chemists who are involved in the drug discovery process."
- John L. Neumeyer, Harvard Medical School, in JOURNAL OF MEDICINAL CHEMISTRY from the American Chemical Society

More Reviews and Recommendations

Biography

Camille-Georges Wermuth PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the "Centre d’Etudes Physio-biologiques Appliquées à la Marine" in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine.

Professor Wermuths’ main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome.

Besides about 300 scientific papers and about 60 patents, Professor Wermuth is co-author or editor of several books including; Pharmacologie Moléculaire, Masson & Cie, Paris; Médicaments Organiques de Synthèse, Masson & Cie, Paris; Medicinal Chemistry for the 21st Century, Bl